Angela Genge, Jesse M Cedarbaum, Jeremy Shefner, Adriano Chio, Ammar Al-Chalabi, Philip Van Damme, Chris McDermott, Jonathan Glass, James Berry, Ruben P A van Eijk, Christina Fournier, Julian Grosskreutz, Jinsy Andrews, Vanessa Bertone, Tommy M Bunte, Mathias Couillard, Cathy Cummings, Gale Kittle, John Polzer, Kristiana Salmon, Corey Straub, Leonard H van den Berg
{"title":"The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.","authors":"Angela Genge, Jesse M Cedarbaum, Jeremy Shefner, Adriano Chio, Ammar Al-Chalabi, Philip Van Damme, Chris McDermott, Jonathan Glass, James Berry, Ruben P A van Eijk, Christina Fournier, Julian Grosskreutz, Jinsy Andrews, Vanessa Bertone, Tommy M Bunte, Mathias Couillard, Cathy Cummings, Gale Kittle, John Polzer, Kristiana Salmon, Corey Straub, Leonard H van den Berg","doi":"10.1080/21678421.2024.2320880","DOIUrl":null,"url":null,"abstract":"<p><p>The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) was developed more than 25 years ago as an instrument to monitor functional change over time in patients with ALS. It has since been revised and extended to meet the needs of high data quality in ALS trials (ALSFRS-R), however a full re-validation of the scale was not completed. Despite this, the scale has remained a primary outcome measure in clinical trials. We convened a group of clinical trialists to discuss and explore opportunities to improve the scale and propose alternative measures. In this meeting report, we present a call to action on the use of the ALSFRS-Revised scale in clinical trials, focusing on the need for (1) harmonization of the ALSFRS-R administration globally, (2) alignment on a set of recommendations for clinical trial design and statistical analysis plans (SAPs), and (3) use of additional outcome measures.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2024.2320880","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) was developed more than 25 years ago as an instrument to monitor functional change over time in patients with ALS. It has since been revised and extended to meet the needs of high data quality in ALS trials (ALSFRS-R), however a full re-validation of the scale was not completed. Despite this, the scale has remained a primary outcome measure in clinical trials. We convened a group of clinical trialists to discuss and explore opportunities to improve the scale and propose alternative measures. In this meeting report, we present a call to action on the use of the ALSFRS-Revised scale in clinical trials, focusing on the need for (1) harmonization of the ALSFRS-R administration globally, (2) alignment on a set of recommendations for clinical trial design and statistical analysis plans (SAPs), and (3) use of additional outcome measures.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
